SFI Acquires Ginsana from Pharmaton to Strengthen Global Position in Clinically Proven Natural Medicine

Bioggio, Switzerland (ots) - Pharmaton and Soho Flordis International
(SFI), an international provider of clinically proven natural
medicines, announced today the acquisition of Ginsana SA, a leader
and innovator in natural medicine products. The acquisition from
Pharmaton, a company of the Boehringer Ingelheim Group, marks an
important milestone in establishing SFI as the leading global
provider of clinically proven natural medicine.

With superior expertise, state-of-the-art facilities and a
complementary line of six natural medicine brands with significant
growth potential, Ginsana helps SFI advance an extensive product
portfolio and new product pipeline through a strong network of
international distributors. These capabilities will enhance SFI's
Mission to give healthcare professionals and patients access to the
best natural medicines supported by clinical studies. Ginsana will
continue to market its products under the Ginsana brand name and
manufacture Pharmaton( products for the Boehringer Ingelheim Group.
The trademark rights of Pharmaton( remain at Pharmaton.

"We are very pleased to have reached this agreement with SFI that
will strengthen the strategic positioning of Ginsana products in the
world markets and ensure our product supply in the years to come"
said Jochen Gann, member of the Verwaltungsrat of Ginsana and Head of
Corporate Finance at Boehringer Ingelheim.

Ginsana headquarters near Lugano in Switzerland will become an SFI
centre for product development, manufacturing and rapid
commercialisation through its worldwide distributor network.

In a corresponding move, SFI today announced the acquisition of
ProThera, a nutritionally focused healthcare company based in Nevada,
U.S., to further build global distribution and gain entry into the
U.S. health care professional market and the growing field of
probiotics.

"The parallel acquisition of Ginsana and ProThera has not only
extended our network and pipeline of natural medicine brands with
great legacy, it allows us to enter into the attractive field of
probiotics," said SFI CEO, Nigel Pollard. "Building on our success in
the southern hemisphere - in Australia and South Africa - we have now
established a strong foundation for expansion in the northern
hemisphere and its main markets, the U.S., Europe, Middle East and
Asia. Switzerland is the ideal location to reflect SFI's dedication
to innovation and the advancement of natural medicines through
healthcare professionals."

About SFI

Soho Flordis International (SFI) is an international provider of
clinically proven natural medicines. An Australian registered
company, SFI is committed to ensuring that people globally have
access to the best natural medicines supported by clinical studies
performed on the exact finished product. Rather than basing claims on
highly variable ingredients this higher standard enables the
selection of safe, appropriate and effective treatments. SFI is
expanding its global presence to achieve its Vision of building the
world's first global brands focused on bringing quality,
evidence-based natural medicines to market through healthcare
professionals, supported by leading edge research and endorsed by
world-class opinion leaders.

About Ginsana

Ginsana SA, located in Bioggio (Switzerland), owned by Pharmaton, a
Boehringer Ingelheim Group company operates in the high-quality
natural health sector, comprising pharmaceutical grade products made
using natural substances and extracts. Ginsana's products are the
result of the most rigorous scientific research and the experience
acquired over many years as well as the skills developed within the
Boehringer Ingelheim Group.

About ProThera

ProThera Incorporated is a nutritionally focused healthcare company
that specialises in the formulation and manufacture of high grade
nutraceuticals and probiotics for exclusive use by healthcare
professionals for their patients.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EUN

print